DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
DiagnaMed Holdings Corp. (OTCQB: DGNMF) has filed a provisional patent application with the U.S. Patent and Trademark Office for novel methods of producing molecular hydrogen to treat neurological and mental health disorders. The patent covers pharmaceutical-based methods and compositions targeting conditions like Dementia, Parkinson's disease, Depression, and Anxiety. The company plans to partner with research institutions and life sciences companies for manufacturing and clinical research, with the product expected to be ready by December 2024. The global hydrogen generation market was valued at $170.14 billion in 2023, with a projected CAGR of 9.3% through 2030. Over 2,000 scientific publications support molecular hydrogen's therapeutic potential, highlighting its antioxidant and neuroprotective properties.
DiagnaMed Holdings Corp. (OTCQB: DGNMF) ha presentato una domanda di brevetto provvisorio presso l'Ufficio Brevetti e Marchi degli Stati Uniti per metodi innovativi di produzione di idrogeno molecolare per trattare disturbi neurologici e della salute mentale. Il brevetto copre metodi e composti basati su farmaci mirati a condizioni come demenza, morbo di Parkinson, depressione e ansia. L'azienda prevede di collaborare con istituzioni di ricerca e aziende delle scienze della vita per la produzione e la ricerca clinica, con il prodotto previsto per essere disponibile entro dicembre 2024. Il mercato globale della generazione di idrogeno è stato valutato 170,14 miliardi di dollari nel 2023, con un CAGR previsto del 9,3% fino al 2030. Oltre 2.000 pubblicazioni scientifiche supportano il potenziale terapeutico dell'idrogeno molecolare, evidenziando le sue proprietà antiossidanti e neuroprotettive.
DiagnaMed Holdings Corp. (OTCQB: DGNMF) ha solicitado una patente provisional ante la Oficina de Patentes y Marcas de EE. UU. para nuevos métodos de producción de hidrógeno molecular para tratar trastornos neurológicos y de salud mental. La patente abarca métodos y composiciones basadas en productos farmacéuticos dirigidos a condiciones como demencia, enfermedad de Parkinson, depresión y ansiedad. La empresa planea asociarse con instituciones de investigación y empresas de ciencias de la vida para la fabricación y la investigación clínica, con el producto previsto para estar listo en diciembre de 2024. El mercado global de generación de hidrógeno fue valorado en 170.14 mil millones de dólares en 2023, con una tasa de crecimiento anual compuesta (CAGR) proyectada del 9,3% hasta 2030. Más de 2,000 publicaciones científicas apoyan el potencial terapéutico del hidrógeno molecular, destacando sus propiedades antioxidantes y neuroprotectoras.
DiagnaMed Holdings Corp. (OTCQB: DGNMF)는 미국 특허청에 신경학적 및 정신 건강 장애 치료를 위한 분자 수소 생산의 새로운 방법에 대한 임시 특허 출원을 완료했습니다. 이 특허는 치매, 파킨슨병, 우울증, 불안과 같은 상태를 목표로 하는 제약 기반 방법 및 조성을 포함합니다. 회사는 제조 및 임상 연구를 위해 연구 기관 및 생명 과학 회사와 협력할 계획이며, 제품은 2024년 12월까지 출시될 예정입니다. 2023년 글로벌 수소 생성 시장 가치는 1,701억 4천만 달러로 평가되었으며, 2030년까지 연평균 성장률(CAGR) 9.3%가 예상됩니다. 2,000개 이상의 과학 출처가 분자 수소의 치료 가능성을 지원하며, 그 항산화 및 신경 보호 특성을 강조합니다.
DiagnaMed Holdings Corp. (OTCQB: DGNMF) a déposé une demande de brevet provisoire auprès de l'Office des brevets et des marques des États-Unis pour des méthodes novatrices de production de hydrogène moléculaire afin de traiter des troubles neurologiques et de santé mentale. Le brevet couvre des méthodes et des compositions basées sur des produits pharmaceutiques ciblant des conditions telles que démence, maladie de Parkinson, dépression et anxiété. La société prévoit de s'associer à des instituts de recherche et à des entreprises de sciences de la vie pour la fabrication et la recherche clinique, avec un produit prévu pour être prêt d'ici décembre 2024. Le marché mondial de la génération d'hydrogène était évalué à 170,14 milliards de dollars en 2023, avec un taux de croissance annuel composé (CAGR) projeté de 9,3 % jusqu'en 2030. Plus de 2 000 publications scientifiques soutiennent le potentiel thérapeutique de l'hydrogène moléculaire, en mettant en lumière ses propriétés antioxydantes et neuroprotectrices.
Die DiagnaMed Holdings Corp. (OTCQB: DGNMF) hat beim US-Patent- und Markenamt einen vorläufigen Patentantrag für neuartige Methoden zur Herstellung von Molekularem Wasserstoff eingereicht, um neurologische und psychische Erkrankungen zu behandeln. Das Patent umfasst arzneimittelbasierte Methoden und Zusammensetzungen, die auf Erkrankungen wie Demenz, Parkinson-Krankheit, Depression und Angst abzielen. Das Unternehmen plant, mit Forschungseinrichtungen und Unternehmen der Lebenswissenschaften für die Herstellung und klinische Forschung zusammenzuarbeiten, wobei das Produkt voraussichtlich bis Dezember 2024 verfügbar sein wird. Der globale Wasserstofferzeugungsmarkt hatte 2023 einen Wert von 170,14 Milliarden US-Dollar und wird bis 2030 einen prognostizierten CAGR von 9,3% erreichen. Über 2.000 wissenschaftliche Publikationen unterstützen das therapeutische Potenzial von Molekularem Wasserstoff und heben dessen antioxidantive und neuroprotektive Eigenschaften hervor.
- Patent application filed for novel molecular hydrogen production methods
- Product launch expected in December 2024
- Operating in a market valued at $170.14B with 9.3% CAGR
- Strong scientific backing with 2,000+ publications and 100+ human studies
- No adverse effects reported in human studies
- No proven clinical efficacy for neurological treatments yet
- Requires third-party partnerships for manufacturing and research
- Company explicitly states no claims about product success or commercial viability
Advancing molecular hydrogen for neurological and mental health disorders
Expects its molecular hydrogen product to be ready for use in December 2024
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics for brain health, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining pharmaceutical-based methods and compositions for producing molecular hydrogen as potential treatments for neurological and mental health disorders.
The patent application, entitled “Methods and Compositions for Producing Hydrogen for Treating Diseases and Disorders Affecting Brain Health,” outlines novel combinations of certain pharmaceutical-grade hydrogen producing ingredients as a potential therapeutic option for a variety of neurological disorders such as, but not limited to, Dementia, Parkinson’s disease, and Traumatic brain injury, and mental health disorders including, Depression, Anxiety, and Post-traumatic stress disorder.
The foundation of DiagnaMed’s strategic initiative to advance therapies that unlock the medical potential of molecular hydrogen for brain health is set for partnering and commercialization. DiagnaMed will partner with third-party research institutions and life sciences companies in the manufacturing, clinical research, and commercialization of its patent-pending molecular hydrogen product. The Company expects its pharmaceutical-grade molecular hydrogen product to be ready for use in December 2024.
“Molecular hydrogen therapy has promising potential for brain health and we are focused on developing a natural, safe and potentially efficacious pharmaceutical-grade molecular hydrogen product for neurological and mental health disorders,” said Fabio Chianelli, CEO of DiagnaMed. “We are now initiating product testing and manufacturing of our molecular hydrogen product for clinical research and commercialization.”
Hydrogen is well-known for its industrial use as a pollution-free fuel. The global hydrogen generation market size was estimated at USD 170.14 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of
Molecular hydrogen therapy is a growing field and poised for rapid clinical adoption. There are over 2,000 scientific publications on molecular hydrogen’s potential therapeutic effects in over 100 human studies2. Molecular hydrogen has been clinically demonstrated to provide antioxidant, anti-inflammatory and neuroprotective effects. It can potentially aid in managing chronic diseases by diminishing oxidative stress and the associated inflammatory pathways. The cellular bioavailability of molecular hydrogen is high3 and has the potential for antiaging, neurodegenerative disorders (i.e. Parkinson’s and Alzheimer’s disease), and mental health conditions (i.e. Depression)4.
According to a published article titled “Molecular hydrogen therapy for neurological diseases: a review of current evidence,” a number of studies have demonstrated the neuroprotective effects of hydrogen therapy in stroke, neurodegenerative diseases, neurotrauma, and global brain injury4. Also, no adverse effects have been reported in the human studies related to the administration of hydrogen therapy and its clinical use as an adjunctive treatment of various neurological diseases is promising5.
The Company cautions that it is not making any express or implied claims about its molecular hydrogen product success alone and in combination with pharmaceuticals in treating neurological and mental health disorders or commercial viability. The patent application seeks protection for, among other things, methods of producing hydrogen alone and in combinations with certain ingredients supporting various brain health diseases, disorders, and conditions.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a life sciences company focused on molecular hydrogen and AI diagnostics for brain health. DiagnaMed is exploring the medical use of hydrogen for brain health conditions, such as neurological and mental health disorders. In addition, the Company is commercializing BRAIN AGE® Brain Health AI Platform, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and nine months ended June 30, 2024 (“MD&A”), dated August 22, 2024, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
Footnotes:
- Grandviewresearch.com. Hydrogen Generation Market Size, Share & Trends Analysis Report By System (Merchant, Captive), By Technology (Steam Methane Reforming, Coal Gasification), By Application, By Source, By Region, And Segment Forecasts, 2024 - 2030. [(accessed on 30 October 2024)]. Available online: https://www.grandviewresearch.com/industry-analysis/hydrogen-generation-market.
- Ichihara, M., et al. Beneficial biological effects and the underlying mechanisms of molecular hydrogen-Comprehensive review of 321 original articles. Med. Gas Res. 2015, 5, 12.
- Nicolson, GI., et al. 2016. Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine. Int. J. Clin. Med. 7(1): 32-76. Doi:10.4236/ijcm.2016.71005.
- Shigeo Ohta, Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine, Pharmacology & Therapeutics,Volume 144, Issue 1, 2014, Pages 1-11, ISSN 0163-7258, https://doi.org/10.1016/j.pharmthera.2014.04.006.
- Ramanathan D, Huang L, Wilson T, Boling W. Molecular hydrogen therapy for neurological diseases: a review of current evidence. Med Gas Res. 2023 Jul-Sep;13(3):94-98. Doi: 10.4103/2045-9912.359677. PMID: 36571372; PMCID: PMC9979207.
FAQ
When will DiagnaMed (DGNMF) launch its molecular hydrogen product?
What conditions will DiagnaMed's (DGNMF) molecular hydrogen product target?
What is the current market size for hydrogen generation according to DiagnaMed (DGNMF)?
How many scientific publications support molecular hydrogen therapy according to DiagnaMed (DGNMF)?
